Kawasaki Disease

  • Paul IshimineEmail author
  • John T. Kanegaye


Kawasaki disease (KD) is an acute vasculitis leading to systemic inflammatory manifestations. The classic clinical criteria of KD include fever persisting at least 5 days and at least four out of five features (extremity changes, polymorphous exanthem, conjunctival injection, oral/lip changes, and cervical lymphadenopathy). Patients with KD will almost always have an elevated C-reactive protein and/or erythrocyte sedimentation rate. KD is treated with immunoglobulin and aspirin with the goal of preventing the development of coronary artery aneurysms.


Vasculitis Cervical lymphadenopathy Conjunctivitis Coronary artery aneurysm Immunoglobulin 


  1. 1.
    Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271–6.PubMedGoogle Scholar
  2. 2.
    Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child. 2015;100:1084–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Makino N, Nakamura Y, Yashiro M, et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011–2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015;25:239–45.CrossRefPubMedGoogle Scholar
  4. 4.
    Callinan LS, Holman RC, Vugia DJ, Schonberger LB, Belay ED. Kawasaki disease hospitalization rate among children younger than 5 years in California, 2003–2010. Pediatr Infect Dis J. 2014;33:781–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, Schonberger LB. Hospitalizations for Kawasaki syndrome among children in the United States, 1997–2007. Pediatr Infect Dis J. 2010;29:483–8.PubMedGoogle Scholar
  6. 6.
    Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Minich LL, Sleeper LA, Atz AM, et al. Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics. 2007;120:e1434–40.CrossRefPubMedGoogle Scholar
  8. 8.
    Chang FY, Hwang B, Chen SJ, Lee PC, Meng CC, Lu JH. Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J. 2006;25:241–4.CrossRefPubMedGoogle Scholar
  9. 9.
    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–e99.CrossRefPubMedGoogle Scholar
  10. 10.
    Yellen ES, Gauvreau K, Takahashi M, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics. 2010;125:e234–41.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gong GW, McCrindle BW, Ching JC, Yeung RS. Arthritis presenting during the acute phase of Kawasaki disease. J Pediatr. 2006;148:800–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Uehara R, Igarashi H, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guerin inoculation site. Pediatr Infect Dis J. 2010;29:430–3.CrossRefPubMedGoogle Scholar
  13. 13.
    Baker AL, Lu M, Minich LL, et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr. 2009;154:592–5 e2.CrossRefPubMedGoogle Scholar
  14. 14.
    Turnier JL, Anderson MS, Heizer HR, Jone PN, Glode MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatrics. 2015;136:e609–14.CrossRefPubMedGoogle Scholar
  15. 15.
    Cohen E, Sundel R. Kawasaki disease at 50 years. JAMA Pediatr. 2016;170:1093–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Lin YJ, Cheng MC, Lo MH, Chien SJ. Early differentiation of Kawasaki disease shock syndrome and toxic shock syndrome in a pediatric intensive care unit. Pediatr Infect Dis J. 2015;34:1163–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Kanegaye JT, Van Cott E, Tremoulet AH, et al. Lymph-node-first presentation of Kawasaki disease compared with bacterial cervical adenitis and typical Kawasaki disease. J Pediatr. 2013;162:1259–63, 63.e1-2.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bayers S, Shulman ST, Paller AS. Kawasaki disease: part I. Diagnosis, clinical features, and pathogenesis. J Am Acad Dermatol. 2013;69:501 e1–11; quiz 11-2.CrossRefGoogle Scholar
  19. 19.
    Eladawy M, Dominguez SR, Anderson MS, Glode MP. Abnormal liver panel in acute Kawasaki disease. Pediatr Infect Dis J. 2011;30:141–4.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tremoulet AH, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC. Evolution of laboratory values in patients with Kawasaki disease. Pediatr Infect Dis J. 2011;30:1022–6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Shike H, Kanegaye JT, Best BM, Pancheri J, Burns JC. Pyuria associated with acute Kawasaki disease and fever from other causes. Pediatr Infect Dis J. 2009;28:440–3.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Printz BF, Sleeper LA, Newburger JW, et al. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol. 2011;57:86–92.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2:1055–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Kim GB, Yu JJ, Yoon KL, et al. Medium- or higher-dose acetylsalicylic acid for acute Kawasaki disease and patient outcomes. J Pediatr. 2017;184:125–9.e1.CrossRefPubMedGoogle Scholar
  27. 27.
    Dallaire F, Fortier-Morissette Z, Blais S, et al. Aspirin dose and prevention of coronary abnormalities in Kawasaki disease. Pediatrics. 2017;139:e20170098.CrossRefPubMedGoogle Scholar
  28. 28.
    Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663–75.CrossRefPubMedGoogle Scholar
  29. 29.
    Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379:1613–20.CrossRefPubMedGoogle Scholar
  30. 30.
    Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. The Cochrane Database Syst Rev. 2017;1:Cd011188.Google Scholar
  31. 31.
    Chen S, Dong Y, Kiuchi MG, et al. Coronary artery complication in Kawasaki disease and the importance of early intervention : a systematic review and meta-analysis. JAMA Pediatr. 2016;170:1156–63.CrossRefPubMedGoogle Scholar
  32. 32.
    Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009;123:e783–9.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Dominguez SR, Friedman K, Seewald R, Anderson MS, Willis L, Glode MP. Kawasaki disease in a pediatric intensive care unit: a case-control study. Pediatrics. 2008;122:e786–90.CrossRefPubMedGoogle Scholar
  34. 34.
    Chen PS, Chi H, Huang FY, Peng CC, Chen MR, Chiu NC. Clinical manifestations of Kawasaki disease shock syndrome: a case-control study. J Microbiol Immunol Infect = Wei mian yu gan ran za zhi. 2015;48:43–50.CrossRefPubMedGoogle Scholar
  35. 35.
    Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379–85.CrossRefPubMedGoogle Scholar
  36. 36.
    Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol. 1996;28:253–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Salgado AP, Ashouri N, Berry EK, et al. High risk of coronary artery aneurysms in infants younger than 6 months of age with Kawasaki disease. J Pediatr. 2017;185:112–6.e1.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Tsuda E, Hamaoka K, Suzuki H, et al. A survey of the 3-decade outcome for patients with giant aneurysms caused by Kawasaki disease. Am Heart J. 2014;167:249–58.CrossRefPubMedGoogle Scholar
  39. 39.
    Daniels LB, Tjajadi MS, Walford HH, et al. Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia. Circulation. 2012;125:2447–53.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Nakamura Y, Aso E, Yashiro M, et al. Mortality among Japanese with a history of Kawasaki disease: results at the end of 2009. J Epidemiol. 2013;23:429–34.CrossRefPubMedGoogle Scholar
  41. 41.
    Holve TJ, Patel A, Chau Q, Marks AR, Meadows A, Zaroff JG. Long-term cardiovascular outcomes in survivors of Kawasaki disease. Pediatrics. 2014;133:e305–11.CrossRefPubMedGoogle Scholar
  42. 42.
    Garcia-Pavon S, Yamazaki-Nakashimada MA, Baez M, Borjas-Aguilar KL, Murata C. Kawasaki disease complicated with macrophage activation syndrome: a systematic review. J Pediatr Hematol Oncol. 2017;39:445–51.CrossRefPubMedGoogle Scholar
  43. 43.
    Maddox RA, Holman RC, Uehara R, et al. Recurrent Kawasaki disease: USA and Japan. Pediatr Int Off J Jpn Pediatr Soc. 2015;57:1116–20.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Departments of Emergency Medicine and PediatricsUniversity of California, San Diego School of MedicineSan DiegoUSA
  2. 2.Department of PediatricsUniversity of California, San Diego School of MedicineSan DiegoUSA

Personalised recommendations